Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)

Eunae Sandra Cho; Fergal J. Moloney; Hong Cai; Annie Au-Yeung; Carlos China; Richard A Scolyer; Benafsha Yosufi; Mark J. Raftery; Jason Z. Deng; Stephen W. Morton; Paula T. Hammond; Hendrik‐Tobias Arkenau; Diona L. Damian; Douglas J. Francis; Colin N. Chesterman; Ross St.C. Barnetson; Gary M. Halliday; Levon M. Khachigian

doi:10.1016/s0140-6736(12)62166-7

Related publications

Article2013

Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)

Eunae Sandra Cho, Hong Cai, Annie Au-Yeung, Carlos China, Benafsha Yosufi, Hendrik‐Tobias Arkenau, Fergal J. Moloney, Richard A Scolyer, Mark J. Raftery, Jason Z. Deng, Stephen W. Morton, Paula T. Hammond, Diona L. Damian, Douglas J. Francis, Colin N. Chesterman, Ross St.C. Barnetson, Gary M. Halliday, Levon M. Khachigian

Article2012

Human 8-oxoguanine-DNA glycosylase-1 is downregulated in human basal cell carcinoma

Xiao Huang, Richard A Scolyer, Askar Abubakar, Gary M. Halliday

Article2012

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

Jordi Bruix, Jean‐Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Antonio Craxı̀, Peter R. Galle, Armando Santoro, Michel Beaugrand, Angelo Sangiovanni, Camillo Porta, Guido Gerken, Jorge A. Marrero, Andrea Nadel, Michael Shan, M. Moscovici, D. Voliotis, Josep M. Llovet

Journal of Hepatology

Article2022

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Stephen L. Chan, Martin Schüler, Yoon‐Koo Kang, Chia‐Jui Yen, Julien Edeline, Su Pin Choo, Chia‐Chi Lin, Takuji Okusaka, Karl-Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean–Frédéric Blanc, Kyung-Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo, Éric Assenat, Andrew X. Zhu, Thomas Yau, Ho Yeong Lim, Jordi Bruix, Andreas Geier,

Article2025

A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T-cell engager, in patients with advanced solid tumors.

Sandra P. D’Angelo, Vivek Subbiah, Jean Yves Blay, Michael J. Wagner, Neeltje Steeghs, Jeonghwan Youk, Hideki Mizusako, Yoshihiro Ohue, Jin Jin, Abdul Waheed Rajper, Nicole Tesar, Patrick Schöffski

Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)

Discussion(0)

Related publications

Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)

Human 8-oxoguanine-DNA glycosylase-1 is downregulated in human basal cell carcinoma

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T-cell engager, in patients with advanced solid tumors.